This document provides a summary and analysis of dermatology partnering deals and agreements since 2007. It details the types of agreements companies typically enter into at different development stages. The majority of deals are discovery-stage licenses where companies license technology for further development. The document also analyzes trends in financial terms like upfront payments, milestones, and royalties by development stage. It provides over 1,500 links to actual dermatology deals and contracts between companies.

1. Dermatology Partnering Terms and Agreements
The Dermatology Partnering Terms and Agreements report provides a detailed understanding and analysis of
how and why companies enter dermatology partnering deals. The majority of deals are discovery, preclinical
or development stage whereby the licensee obtains a right or an option right tlicense the licensors dermatology
technology. These deals tend tbe multicomponent, starting with collaborative R&D, and commercialization of
outcomes. This report provides details of the latest dermatology deals and contracts announced in the
healthcare sectors. Understanding the flexibility of a prospective partner’s negotiated deals terms
provides critical insight intthe negotiation process in terms of what you can expect tachieve during the
negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil
is in the detail in terms of how payments are triggered – contract documents provide this insight where
press releases and databases dnot. The report includes an analysis of financial deal terms by stage at signing
covering headline value, upfront payment, milestone payments and royalty rates. The initial chapters of this
report provide an orientation of dermatology dealmaking and business activities. Chapter 1 provides an
introduction tthe report. Chapter 2 provides an overview of the trends in dermatology dealmaking since 2007
covering trends by year, deal type, stage of development, technology type and therapeutic indication. In
addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value,
upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of
values for each stage of development. Chapter 3 provides a review of the leading dermatology deals since
2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all
biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online
access tthe contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a
brief summary followed by a comprehensive listing of dermatology deals, as well as contract documents
available in the public domain. Where available, each deal title links via Weblink tan online version of the
actual contract document, providing easy access teach contract document on demand. Chapter 5 provides
comprehensive access tall dermatology deals since 2007 where a deal contract is available, providing the user
with direct access tcontracts as filed with the SEC regulatory authorities. Each deal title links via Weblink tan
online version of the deal record contract document, providing easy access teach contract document on
demand. Chapter 6 provides a comprehensive directory of all dermatology partnering deals signed and
announced since 2007. The chapter is organized by specific dermatology therapy focus. Each deal title links
via Weblink tan online version of the deal record and where available, the contract document, providing easy
access teach contract document on demand. In addition, a comprehensive appendix is provided with each
report of all dermatology partnering deals signed and announced since 2007. The appendices are organized by
company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc)
and technology type. Each deal title links via Weblink tan online version of the deal record and where
available, the contract document, providing easy access teach contract document on demand. The report
alsincludes numerous tables and figures that illustrate the trends and activities in dermatology partnering and
dealmaking since 2007. In conclusion, this report provides everything a prospective dealmaker needs tknow
about partnering in the research, development and commercialization of dermatology technologies and
products.
Key benefits Dermatology Partnering Terms and Agreementsprovides the reader with the following key
Dermatology Partnering Terms and Agreements

2. benefits: In-depth understanding of dermatology deal trends since 2007 Access dermatology deal headline,
upfront, milestone and royalty data Research hundreds of actual contracts between dermatology partner
companies Comprehensive access tover 1500 links tactual dermatology deals entered intby the world’s
biopharma companies Indepth review of dermatology deals entered intby the leading fifty bigpharma
companies Benchmark the key deal terms companies have agreed in previous deals Identify key terms under
which companies partner dermatology opportunities Uncover companies actively partnering dermatology
opportunities Report scope Dermatology Partnering Terms and Agreements is intended tprovide the reader
with an in-depth understanding and access tdermatology trends and structure of deals entered intby leading
companies worldwide. Dermatology Partnering Terms and Agreements includes:
Trends in dermatology dealmaking in the biopharma industry since 2007 Analysis of dermatology deal
structure Access theadline, upfront, milestone and royalty data Access thundreds of dermatology deal contract
documents Comprehensive access tover 1500 dermatology deal records The leading dermatology deals by
value since 2007 Most active dermatology dealmakers since 2007 In Dermatology Partnering Terms and
Agreements, available deals and contracts are listed by:
Headline value Upfront payment value Royalty rate value Stage of development at signing Deal component
type Technology type Specific therapy indication
table Of Contents
executive Summary
chapter 1 – Introduction
chapter 2 – Trends In Dermatology Dealmaking
2.1. Introduction
2.2. Dermatology Partnering Over The Years
2.3. Bigpharma Dermatology Dealmaking Activity
2.4. Bigpharma Not Active In Dermatology
2.5. Dermatology Partnering By Deal Type
2.6. Dermatology Partnering By Industry Sector
2.7. Dermatology Partnering By Stage Of Development
2.8. Dermatology Partnering By Technology Type
2.9. Dermatology Partnering By Dermatology Indication
2.10. Average Deal Terms For Dermatology
2.10.1 Dermatology Headline Values
2.10.2 Dermatology Upfront Payments
2.10.3 Dermatology Milestone Payments
2.10.4 Dermatology Royalty Rates
chapter 3 – Leading Dermatology Deals
3.1. Introduction
3.2. Top Dermatology Deals By Value
3.3. Top Dermatology Deals Involving Bigpharma
Dermatology Partnering Terms and Agreements

3. chapter 4 – Bigpharma Dermatology Deals
4.1. Introduction
4.2. How To Use Bigpharma Partnering Deals
4.3. Bigpharma Dermatology Partnering Company Profiles
abbott
actavis
actelion
allergan
amgen
astellas
astrazeneca
baxter International
bayer
bristol-myers
squibb C
elgene
eli Lilly
endo Pharmaceuticals
forest Laboratories
galderma
glaxosmithkline
hospira
johnson & Johnson
merck & Co
merck Kgaa
mitsubishi Tanabe
novartis
pfizer
roche
sanofi
shionogi
shire
teva
warner Chilcott
watson
chapter 5 – Dermatology Partnering Contracts Directory
5.1. Introduction
5.2. By Deal Type
asset Purchase
assignment
bigpharma Outlicensing
Dermatology Partnering Terms and Agreements

4. co-development
collaborative R&d
co-market
contract Service
co-promotion
development
distribution
equity Purchase
joint Venture
licensing
litigation
loan
manufacturing
marketing
option
promotion
research
settlement
sub-license
supply
termination
5.3. By Stage Of Development
discovery
formulation
marketed
phase I
phase Ii
phase Iii
preclinical
5.4. By Technology Type
antibodies
assays
biologicalcompounds
biomaterials
clinical Testing
devices
diagnostics
dna Probes
drug Delivery
enabling Technology
equipment
genomics
natural Product
Dermatology Partnering Terms and Agreements

5. oligonucleotide
orphan Drug
peptides
processes
recombinant Dna
regenerative Medicine
research Services
research Supplies
screening
small Molecules
stem Cells
chapter 6 – Dermatology Dealmaking By Indication
6.1. Introduction
6.2. Deals By Therapeutic Indication
dermatology
acne
actinickeratosis
angioedema
burns
cellulitis
cosmetics
dermatitis
diabetic Foot Ulcer
eczema Hair Disorders
impetigo
itching
nail Disorders
psoriasis Rosacea
sun Damage
rash Scar
venous Ulcer
wound Healing
wrinkles
chapter 7 – Partnering Resource Center
7.1. Online Partnering
7.2. Partnering Events
7.3. Further Reading On Dealmaking
appendices
appendix 1 – Directory Of Dermatology Deals By Company A-z 2007-2012
appendix 2 – Directory Of Dermatology Deals By Deal Type 2007-2012
Dermatology Partnering Terms and Agreements

6. asset Purchase
assignment
bigpharma Outlicensing
co-development
collaborative R&d
co-market
contract Service
co-promotion
crada
cross-licensing
development
distribution
equity Purchase
evaluation
grant
joint Venture
licensing
litigation
loan
manufacturing
manufacturing - Oem
marketing
material Transfer
option
promotion
research
royalty Financing
settlement
spin Out
sub-license
supply
technology Transfer
termination
warranty
appendix 3 - Directory Of Dermatology Deals By Stage Of Development 2007-2012
appendix 4 – Directory Of Dermatology Deals By Technology Type 2007
appendix 5 – Deal Type Definitions
about Wildwood Ventures
current Partnering
current Agreements
recent Titles From Currentpartnering
order Form – Reports
Dermatology Partnering Terms and Agreements

7. ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research
reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our
huge collection of market research reports. We provide our services to all sizes of organizations and across all
industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as
publishers and will assist you in making an informed decision by giving you unbiased and deep insights on
which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Dermatology Partnering Terms and Agreements